GlassScriptPhysician profile
Kathleen Powers
NPI 1245610369
$1,933.19
in general payments reported to CMS, 2019-2025
31 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.29 · 2020: $20.01 · 2021: $108 · 2022: $349 · 2023: $466 · 2024: $590 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.81 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $430.21 | 2021-2024 | Nexplanon |
| Astellas Pharma US INC | $193.03 | 2023-2024 | Veozah |
| Hologic Sales and Service, LLC | $175.10 | 2023-2025 | Aptima, Myosure Tissue Removal Device, Acessa Provu System |
| Mayne Pharma Commercial LLC | $116.85 | 2023-2025 | |
| Millicent US INC | $108.16 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Coopersurgical, INC. | $75.97 | 2021-2024 | Paragard T 380a |
| Exeltis, USA INC. | $67.25 | 2021-2025 | Slynd |
| Channel Medsystems, INC. | $60.59 | 2023 | |
| Biogen, INC. | $57.37 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $57.11 | 2024-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $48.86 | 2022-2025 | |
| Baxter Healthcare | $45.76 | 2024 | Perclot |
| Pfizer INC. | $39.76 | 2024-2025 | |
| Amag Pharmaceuticals, INC. | $39.12 | 2019 | |
| Teleflex LLC | $38.51 | 2025 | Quikclot |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $37.64 | 2020-2022 | |
| Daiichi Sankyo INC. | $37.09 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $33.54 | 2023-2024 | Gardasil 9, Gardasil |
| Therapeuticsmd, INC. | $30.22 | 2021-2022 | |
| Minerva Surgical, INC | $29.35 | 2023 | |
| Lupin INC. | $28.12 | 2019 | |
| Gynesonics, INC. | $22.34 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Meditrina | $22.10 | 2025 | |
| Aspira Women'S Health INC | $21.74 | 2024 | Ova1 |
| Kowa Pharmaceuticals America, INC. | $21.00 | 2023 | Seglentis |
| Smith+Nephew, INC. | $18.04 | 2024 | Pico 7, Pico 14 |
| Mylan Pharmaceuticals INC. | $17.23 | 2022 | |
| Evofem Biosciences, INC. | $17.21 | 2022 | |
| Boston Scientific Corporation | $16.98 | 2022 | |
| Seqirus USA INC | $13.91 | 2024 | Flucelvax |
| Myovant Sciences INC. | $13.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.